Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival.

  title={Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival.},
  author={A. Venkata Narayana and Patrick Kelly and J G Golfinos and Erik C. Parker and G Blake Johnson and Edmond A Knopp and David Zagzag and Ingeborg Fischer and Shahzad Raza and Praveen K Medabalmi and Patricia Eagan and Michael L. Gruber},
  journal={Journal of neurosurgery},
  volume={110 1},
OBJECT Antiangiogenic agents have recently shown impressive radiological responses in high-grade glioma. However, it is not clear if the responses are related to vascular changes or due to antitumoral effects. The authors report the mature results of a clinical study of bevacizumab-based treatment of recurrent high-grade gliomas. METHODS Sixty-one patients with recurrent high-grade gliomas received treatment with bevacizumab at 10 mg/ kg every 2 weeks for 4 doses in an 8-week cycle along with… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 124 extracted citations

Computational Modeling of Tumor Response to Vascular-Targeting Therapies—Part I: Validation

Comp. Math. Methods in Medicine • 2011
View 12 Excerpts
Highly Influenced

Judah Folkman

Springer International Publishing • 2018

Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial

Journal of Cancer Research and Clinical Oncology • 2018
View 3 Excerpts


Publications referenced by this paper.
Showing 1-10 of 30 references

A phase II safety study of bevacizumab in patients with mul tiple recurrent or progressive malignant gliomas

JJ Raizer, L Callot, +3 authors C Getch
J Clin On col • 2007

Bevacizumab for advanced breast cancer . Hematol Oncol

D Vignjevic, M Schoumacher, +3 authors M Laé

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2007

Comparing cerebral blood volume and vascular permeability measurements with tumor volume measurements following anti-angiogenesis therapy in recurrent gliomas

A Narayana, S Chheang, +3 authors G Johnson
J Clin Oncol • 2007

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma

JJ Vredenburgh, A Desjardins, +3 authors JA Quinn
Clin Cancer Res • 2007

Angiogenesis-independent tumor growth mediated by stem-like cancer cells.

Proceedings of the National Academy of Sciences of the United States of America • 2006

Similar Papers

Loading similar papers…